Kidney cancer, of which renal cell cancer (RCC) is the most common form, accounts for just under 2% of newly diagnosed malignancies worldwide. When detected early, surgery is the most efficacious treatment for patients with nonmetastatic, localised RCC, but for patients with large tumours, regional lymph node involvement, or inferior vena cava (IVC) tumour thrombus, complete tumour resection can be challenging and surgical resection alone is often insufficient to prevent disease recurrence. For patients who experience recurrence or develop metastatic disease, treatment options are limited and the prognosis is extremely poor. In this article, treatment options for different types of patients with RCC are deliberated. For patients with IVC tumour thrombus, the various approaches and use of embolisation are discussed. Immunotherapy and novel, targeted agents are examined as treatment options for patients with metastatic disease. For patients medically unsuitable for radical surgery, other alternatives including nephron-sparing surgery (partial nephrectomy, cryoablation, and radiofrequency ablation) and observation with supportive care are discussed. (c) 2006 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Current and future trends in the treatment of renal cancer / Thomas, Keane; David, Gillatt; Christopher P., Evans; Tubaro, Andrea. - In: EUROPEAN UROLOGY. SUPPLEMENTS. - ISSN 1569-9056. - 6:3(2007), pp. 374-384. (Intervento presentato al convegno Joint Meeting of the European-Association-for-Urology/AstraZeneca on Challenges in the Management of Urological Cancers tenutosi a Amsterdam, NETHERLANDS nel JUL, 2006) [10.1016/j.eursup.2006.12.006].

Current and future trends in the treatment of renal cancer

TUBARO, ANDREA
2007

Abstract

Kidney cancer, of which renal cell cancer (RCC) is the most common form, accounts for just under 2% of newly diagnosed malignancies worldwide. When detected early, surgery is the most efficacious treatment for patients with nonmetastatic, localised RCC, but for patients with large tumours, regional lymph node involvement, or inferior vena cava (IVC) tumour thrombus, complete tumour resection can be challenging and surgical resection alone is often insufficient to prevent disease recurrence. For patients who experience recurrence or develop metastatic disease, treatment options are limited and the prognosis is extremely poor. In this article, treatment options for different types of patients with RCC are deliberated. For patients with IVC tumour thrombus, the various approaches and use of embolisation are discussed. Immunotherapy and novel, targeted agents are examined as treatment options for patients with metastatic disease. For patients medically unsuitable for radical surgery, other alternatives including nephron-sparing surgery (partial nephrectomy, cryoablation, and radiofrequency ablation) and observation with supportive care are discussed. (c) 2006 European Association of Urology. Published by Elsevier B.V. All rights reserved.
2007
immunotherapy; inferior vena cava; laparoscopic nephrectomy; partial nephrectomy; radical nephrectomy; renal cell cancer; renal metastases; thrombus
01 Pubblicazione su rivista::01a Articolo in rivista
Current and future trends in the treatment of renal cancer / Thomas, Keane; David, Gillatt; Christopher P., Evans; Tubaro, Andrea. - In: EUROPEAN UROLOGY. SUPPLEMENTS. - ISSN 1569-9056. - 6:3(2007), pp. 374-384. (Intervento presentato al convegno Joint Meeting of the European-Association-for-Urology/AstraZeneca on Challenges in the Management of Urological Cancers tenutosi a Amsterdam, NETHERLANDS nel JUL, 2006) [10.1016/j.eursup.2006.12.006].
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/106674
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 9
  • ???jsp.display-item.citation.isi??? 13
social impact